In vitro platelet aggregation defects in patients with myeloproliferative disorders and high platelet counts: Are they laboratory artefacts?

Claudio Grignani, Patrizia Noris, Carmine Tinelli, Giovanni Barosi, Carlo L. Balduini

Research output: Contribution to journalArticle

Abstract

It has been recently shown that in vitro platelet aggregation is inhibited when platelet concentration in platelet-rich plasma (PRP) is "normalized" by the addition of platelet-poor plasma (PPP). In this study we tested the hypothesis that the large amount of PPP required to "normalize" PRP in patients with thrombocytosis may result in falsely defective platelet function. To this end, we evaluated platelet aggregation in PRP samples "normalized" with either PPP or buffer in 16 patients with high platelet counts induced by myeloproliferative disorders. Comparison with the results obtained in healthy subjects demonstrated that patients had reduced platelet responses to ADP or collagen in PRP/PPP samples, but normal responses in PRP/buffer. By contrast, the majority of patients had severely defective platelet response to epinephrine independently from the methodological approach. We suggest that the reduced in vitro platelet aggregation previously described in patients with myeloproliferative disorders and thrombocytosis partially derived from a laboratory artefact.

Original languageEnglish
Pages (from-to)131-134
Number of pages4
JournalPlatelets
Volume20
Issue number2
DOIs
Publication statusPublished - Mar 2009

Fingerprint

Myeloproliferative Disorders
Platelet Count
Platelet Aggregation
Artifacts
Blood Platelets
Platelet-Rich Plasma
Thrombocytosis
Buffers
In Vitro Techniques
Adenosine Diphosphate
Epinephrine
Healthy Volunteers
Collagen

Keywords

  • Laboratory artefact
  • Myeloproliferative disorders
  • Platelet aggregation
  • Thrombosis

ASJC Scopus subject areas

  • Hematology

Cite this

@article{442a826367474975bc16281953283409,
title = "In vitro platelet aggregation defects in patients with myeloproliferative disorders and high platelet counts: Are they laboratory artefacts?",
abstract = "It has been recently shown that in vitro platelet aggregation is inhibited when platelet concentration in platelet-rich plasma (PRP) is {"}normalized{"} by the addition of platelet-poor plasma (PPP). In this study we tested the hypothesis that the large amount of PPP required to {"}normalize{"} PRP in patients with thrombocytosis may result in falsely defective platelet function. To this end, we evaluated platelet aggregation in PRP samples {"}normalized{"} with either PPP or buffer in 16 patients with high platelet counts induced by myeloproliferative disorders. Comparison with the results obtained in healthy subjects demonstrated that patients had reduced platelet responses to ADP or collagen in PRP/PPP samples, but normal responses in PRP/buffer. By contrast, the majority of patients had severely defective platelet response to epinephrine independently from the methodological approach. We suggest that the reduced in vitro platelet aggregation previously described in patients with myeloproliferative disorders and thrombocytosis partially derived from a laboratory artefact.",
keywords = "Laboratory artefact, Myeloproliferative disorders, Platelet aggregation, Thrombosis",
author = "Claudio Grignani and Patrizia Noris and Carmine Tinelli and Giovanni Barosi and Balduini, {Carlo L.}",
year = "2009",
month = "3",
doi = "10.1080/09537100802691544",
language = "English",
volume = "20",
pages = "131--134",
journal = "Platelets",
issn = "0953-7104",
publisher = "Taylor & Francis",
number = "2",

}

TY - JOUR

T1 - In vitro platelet aggregation defects in patients with myeloproliferative disorders and high platelet counts

T2 - Are they laboratory artefacts?

AU - Grignani, Claudio

AU - Noris, Patrizia

AU - Tinelli, Carmine

AU - Barosi, Giovanni

AU - Balduini, Carlo L.

PY - 2009/3

Y1 - 2009/3

N2 - It has been recently shown that in vitro platelet aggregation is inhibited when platelet concentration in platelet-rich plasma (PRP) is "normalized" by the addition of platelet-poor plasma (PPP). In this study we tested the hypothesis that the large amount of PPP required to "normalize" PRP in patients with thrombocytosis may result in falsely defective platelet function. To this end, we evaluated platelet aggregation in PRP samples "normalized" with either PPP or buffer in 16 patients with high platelet counts induced by myeloproliferative disorders. Comparison with the results obtained in healthy subjects demonstrated that patients had reduced platelet responses to ADP or collagen in PRP/PPP samples, but normal responses in PRP/buffer. By contrast, the majority of patients had severely defective platelet response to epinephrine independently from the methodological approach. We suggest that the reduced in vitro platelet aggregation previously described in patients with myeloproliferative disorders and thrombocytosis partially derived from a laboratory artefact.

AB - It has been recently shown that in vitro platelet aggregation is inhibited when platelet concentration in platelet-rich plasma (PRP) is "normalized" by the addition of platelet-poor plasma (PPP). In this study we tested the hypothesis that the large amount of PPP required to "normalize" PRP in patients with thrombocytosis may result in falsely defective platelet function. To this end, we evaluated platelet aggregation in PRP samples "normalized" with either PPP or buffer in 16 patients with high platelet counts induced by myeloproliferative disorders. Comparison with the results obtained in healthy subjects demonstrated that patients had reduced platelet responses to ADP or collagen in PRP/PPP samples, but normal responses in PRP/buffer. By contrast, the majority of patients had severely defective platelet response to epinephrine independently from the methodological approach. We suggest that the reduced in vitro platelet aggregation previously described in patients with myeloproliferative disorders and thrombocytosis partially derived from a laboratory artefact.

KW - Laboratory artefact

KW - Myeloproliferative disorders

KW - Platelet aggregation

KW - Thrombosis

UR - http://www.scopus.com/inward/record.url?scp=61649084981&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=61649084981&partnerID=8YFLogxK

U2 - 10.1080/09537100802691544

DO - 10.1080/09537100802691544

M3 - Article

C2 - 19235056

AN - SCOPUS:61649084981

VL - 20

SP - 131

EP - 134

JO - Platelets

JF - Platelets

SN - 0953-7104

IS - 2

ER -